Category Medicine and Healthcare

Trump Holds the Rescheduling Key: Will Marijuana Reform Follow the Patient's Right to Try Path?
Press Release

Trump Holds the Rescheduling Key: Will Marijuana Reform Follow the Patient's Right to Try Path?

From ‘Right to Try' to Cannabis: Trump's Next Breakthrough Could Unlock FDA Trials.

"President Trump's marijuana decision must go beyond politics-patients suffering from Huntington's disease and Multiple Sclerosis have waited nearly a decade for access to MMJ International Holdings' FDA-approved clinical trials. With capsules manufactured and science in place, all that's missing is the DEA stepping aside." stated Duane Boise, CEO MMJ International Holdings.

Read More
This DEA Marijuana Story Is So Bizarre and Twisted! Will President Trump Reschedule?
Press Release

This DEA Marijuana Story Is So Bizarre and Twisted! Will President Trump Reschedule?

Following a landmark court ruling against the Department Of Labor, Duane Boise, CEO of MMJ International Holdings exposes the DEA's identical use of unconstitutional in house courts to paralyze medical cannabis research for Huntington's and Multiple Sclerosis patients.

Read More
Press Release

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs

Canalevia® (crofelemer delayed-release tablets), under the name Canalevia®-CA1, is conditionally approved by the FDA for treatment of CID in dogs

Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally

Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs

Enrollment has reached approximately 25% in Jaguar's ongoing field study of Canalevia-CA1 in dogs

Read More
Press Release

Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders

Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register

As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome (SBS-IF) patient by up to 12.5%; FDA meeting resulted in planned Jaguar regulatory pathway to complete supplemental NDA strategy for crofelemer for patients with metastatic breast cancer, a population meeting orphan definition in US

Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's orphan indication products, resulting in non-dilutive funding for Jaguar

Read More
Press Release

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)

As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating MVID patient by up to 27%; abstract describing results accepted for presentation at upcoming North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2025 Annual Meeting in Chicago

Read More
Pres. Trump's Chance to Fix DEA's Marijuana Policy Failures: Rescheduling?
Press Release

Pres. Trump's Chance to Fix DEA's Marijuana Policy Failures: Rescheduling?

DEA Administrator Terrance Cole has also signaled a tough line: "Everybody knows my stance on marijuana after 30 plus years in law enforcement, so don't even ask!" However, with all due respect to law enforcement, you can't fight a disease with a badge.

MMJ is developing FDA regulated medicine, not an illicit substance. We are the science, and our mission is to treat patients, not to police a plant." Duane Boise, CEO MMJ International Holdings.

Read More
Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
Press Release

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

  • According to the NIH, Acute myocardial infarction (AMI) is a major cause of death, affecting nearly 3 million Americans each year and resulting in over a million deaths

  • Trial demonstrates dramatically higher and more rapid therapeutic impact compared to standard chewed aspirin tablets in clinical trial

  • Aspire's sublingual aspirin was safe and well-tolerated

  • Aspire plans to review clinical trial results with the FDA to enable a potential regulatory submission for accelerated approval

Read More